Former President and Chief Executive Officer · Enliven Therapeutics, Inc. (ELVN)

Rahul Ballal

A named executive officer of Enliven Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,865,809

Salary $113,874Stock awards $0

FY2022: $1,149,681

4th of 4 named executive officers at Enliven Therapeutics by FY2023 total.

4 named officers on file for Enliven Therapeutics, FY2023

Rahul Ballal’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Enliven Therapeutics’s whole pay program stands against its peers

  • Enliven Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELVN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Rahul Ballal’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Rahul Ballal compensation by year

Enliven Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Enliven Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$421,806$436,687$517,729$547,917$113,874
Bonus$153,000$177,289$232,978$275,000$0
Stock awards$0$0$0$181,332$0
Option awards$1,446,110$0$1,189,482$135,342$499,889
Non-equity incentive$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0
All other$5,453$11,620$10,840$10,090$1,252,046
Total$2,026,369$625,596$1,951,029$1,149,681$1,865,809

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Enliven Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001193125-24-117969, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Enliven Therapeutics, Inc. filed document, accession 0001193125-24-117969. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$2.0M
$626K
$2.0M
$1.1M
$1.9M
FY19
FY20
FY21
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option19,910—$25.28
Option10,420—$52.20
Option18,481—$5.52
Option1,566—$19.68

Per the Outstanding Equity Awards at Fiscal Year-End table in Enliven Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

7 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-12Grant or award derivative—17,126$0.0017,126
2025-02-06Grant or award derivative—20,491$0.0020,491
2024-10-08Exercise or conversion derivative10b5-14,106$0.0012,322
2024-10-08Exercise or conversion10b5-16,314$19.6828,655
2024-10-08Exercise or conversion10b5-14,106$5.5232,761
2024-10-08Sale10b5-110,420$28.1722,341
2024-10-08Exercise or conversion derivative10b5-16,314$0.0069,428

The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Enliven Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Sam KintzPresident and Chief Executive Officer$8,279,751
Helen CollinsChief Medical Officer$4,064,839
Joseph LyssikatosChief Scientific Officer$4,011,320
Rahul Ballal · this pageFormer President and Chief Executive Officer$1,865,809

Board service

Enliven Therapeutics board · FY2023–FY2025
Director compensation in US dollars, as Enliven Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$40,000—$324,985—$364,985
FY2024$35,000—$249,890—$284,890
FY2023—————

Each year as the company reported it in Enliven Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Enliven Therapeutics pays directors a $40,000 cash retainer and $325,000 in Options. As stated in Enliven Therapeutics's FY2025 proxy.

The full Enliven Therapeutics compensation record

free company brief

This page is one person within Enliven Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Enliven Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rahul Ballal's compensation dossier · One-time report. No refunds.